Evidence map›Paper›PMID 19882098›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2010

Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry.

Ralf Zahn, Christian W Hamm, Uwe Zeymer, Gert Richardt, Malte Kelm, Benny Levenson, Tassilo Bonzel, Ulrich Tebbe, Georg Sabin, Christoph A Nienaber and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model.Clinical research in cardiology : official journal of the German Cardiac Society · 2013
    Article
  3. Article
  4. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points.Clinical research in cardiology : official journal of the German Cardiac Society · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 3 countries.

Ralf ZahnMed. Klinik B, Kardiologie/Pneumologie/Angiologie/Internistische Intensivmedizin, Herzzentrum Ludwigshafen, Bremserstrasse 79, 67063 Ludwigshafen, Germany. erzahn@aol.com
Christian W Hamm
Uwe Zeymer
Gert Richardt
Malte Kelm
Benny Levenson
Tassilo Bonzel
Ulrich Tebbe
Georg Sabin
Christoph A Nienaber
Thomas Pfannebecker
Jochen Senges
Klinikum Ludwigshafen · DECommunity Research and Development Information Service · BEDeutsches Herzzentrum der Charité · DEDüsseldorf University Hospital · DEElisabeth-Krankenhaus Essen · DEKerckhoff Klinik · DEKlinikum Fulda · DEKlinikum Lippe · DEOrthopädische Praxis · DESegeberger Kliniken · DEUniversitätsmedizin Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of restenosis following intracoronary brachytherapy (ICB) is still a challenging problem. Implantation of sirolimus-eluting stents (SES) in this setting may be an option to be evaluated. METHODS AND

resultsWe analysed the prospective multicentre SES registry, the German Cypher Stent Registry. 7,445 patients treated with an SES during percutaneous coronary intervention (PCI) were registered. Out of these patients, 61 (0.8%) were treated for restenosis after ICB: 56 patients with completed follow-up could be evaluated. Median age was 65 years, with 80% male patients. 48% of patients had a prior myocardial infarction and 25% had already coronary bypass surgery (CABG). Type B2 lesion was present in 40% and type C lesion in 22.4%. Event rates from SES implantation until 6.6 months follow-up were death 0%, myocardial infarction 3.6%, stroke 2.1%. Target vessel revascularization rate (TVR) was 16.4%, and major adverse cardiovascular or cerebral events (MACCE) or TVR occurred in 17.9% of patients. This TVR rate was higher compared with that of other patients treated with an SES: 8.4% (P = 0.04). During 65 months follow-up MACCE or TVR occurred in 44.6% of patients.

conclusionsThe treatment of lesions after ICB occurred in 0.8% out of all patients treated with an SES. Clinical event rates during early follow-up were low. However, the TVR rate was 16.4%, which was significantly higher when compared with other SES-treated patients (8.4%, P = 0.04). The treatment of restenosis after ICB with SES seems to be safe and reasonably effective; however, there might be a late catch-up phenomenon.

Indexed as

RegistriesAgedBlood Vessel ProsthesisBrachytherapyCoronary RestenosisDrug-Eluting StentsFemaleGermanyHumansMaleMiddle AgedPrevalenceProspective StudiesRisk AssessmentRisk FactorsSirolimusSirolimus

Identifiers

PMID19882098
OpenAlexW2005364237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.